ArticleFrontiers in oncology2026
Is sentinel lymph node frozen section analysis necessary in hormone receptor-positive, HER2-negative, clinically node-negative breast cancer patients undergoing upfront mastectomy?
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Axillary surgical management in breast cancer has recently shifted toward less invasive approaches. Although sentinel lymph node biopsy (SLNB) remains the standard method for axillary staging in clinically node-negative patients, the necessity of performing intraoperative frozen section (IFS) in those undergoing up-front mastectomy continues to be a matter of debate. Method: In this retrospective study, we evaluated 47 women aged 18 years or older who were diagnosed with hormone receptor-positive, HER2-negative cT1-3 breast cancer patients and underwent upfront mastectomy combined with SLNB between October 2022 - January 2026. Our analyses excluded patients who received neoadjuvant therapy, underwent breast-conserving surgery, or demonstrated clinical or radiological evidence of nodal involvement. SLNB was performed using a dual-agent technique. In line with institutional routine practice, SLNB were assessed on paraffin-embedded permanent sections rather than IFS analysis. We analyzed treatment processes together with clinical and pathological variables. Results: Among 47 patients, 39 (83%) were node-negative, while 8 (17%) were node-positive. There were no significant differences between the groups by age, tumor size, histopathologic subtype. Lymphovascular invasion and extracapsular extension were significantly more prevalent in SLNB-positive patients (p = 0.021). None of the node-positive patients underwent axillary dissection; instead, a multidisciplinary tumor board decision was to maintain treatment with axillary radiotherapy. The absence of IFS analysis neither altered therapeutic planning nor necessitated any additional surgical intervention. There were no regional recurrences after a median follow-up of 27 months. Conclusion: In this retrospective cohort of clinically node-negative, hormone receptor-positive, HER2-negative cT1-3 breast cancer patients undergoing upfront mastectomy, omission of intraoperative frozen section (IFS) analysis was not associated with early regional recurrence during the observed follow-up. Routine IFS would likely have altered immediate surgical management in only a small minority of patients in this selected population, suggesting limited clinical utility in similar low-risk cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.